NY State Assembly Bill 2013-A2192A

Assembly Bill A2192A

2013-2014 Legislative Session

Authorizes optometrists to prescribe certain drugs that may be used for therapeutic purposes and taken orally

download bill text pdf

Archive: Last Bill Status - In Assembly Committee

Introduced
- In Committee Assembly
- In Committee Senate
- On Floor Calendar Assembly
- On Floor Calendar Senate
- Passed Assembly
- Passed Senate
Delivered to Governor
Signed By Governor

Please enter your contact information

First Name

Last Name

Email Address

A valid email address is required.

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

View Actions

	Assembly Actions - Lowercase Senate Actions - UPPERCASE
May 28, 2014	print number 2192a
May 28, 2014	amend and recommit to higher education
Jan 08, 2014	referred to higher education
Jan 09, 2013	referred to higher education

Bill Amendments

Original

A (Active)

co-Sponsors

View additional co-sponsors

multi-Sponsors

View additional multi-sponsors

2013-A2192 - Details

See Senate Version of this Bill:: S7678
Current Committee:: Assembly Higher Education
Law Section:: Education Law
Laws Affected:: Amd §7101-a, Ed L
Versions Introduced in Other Legislative Sessions:: 2009-2010: A3718
2011-2012: A363

2013-A2192 - Summary

Authorizes optometrists certified to use therapeutic pharmaceutical agents for the treatment or prevention of ocular disease, to also use specified oral pharmaceutical agents in their practices; requires completion of a 30 hour phase three therapeutic pharmaceutical agent certification course; permits the commissioner of health to recommend other categories of drugs that may also be prescribed.

2013-A2192 - Bill Text download pdf

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                  2192

                       2013-2014 Regular Sessions

                          I N  A S S E M B L Y

                               (PREFILED)

                             January 9, 2013
                               ___________

Introduced  by  M.  of  A.  PAULIN,  COOK, CYMBROWITZ, TITONE, ABINANTI,
  GUNTHER, GABRYSZAK, FARRELL, WEPRIN, HEVESI -- Multi-Sponsored  by  --
  M.  of  A. BOYLAND, CAHILL, ENGLEBRIGHT, FRIEND, GALEF, GOODELL, GOTT-
  FRIED, HIKIND, MAISEL, RIVERA, SIMANOWITZ -- read once and referred to
  the Committee on Higher Education

AN ACT to amend the education law, in relation to the practice of  opto-
  metry

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1.   Subparagraph (v) of paragraph (d)  of  subdivision  1  of
section 7101-a of the education law, as added by chapter 517 of the laws
of  1995,  is  amended  and  a new subparagraph (vi) is added to read as
follows:
  (v) Disclosing agents and other substances used  in  conjunction  with
these drugs as part of a diagnostic procedure[.];
  (VI)  SUCH ADDITIONAL CATEGORIES OF DRUGS AS MAY BE RECOMMENDED BY THE
COMMISSIONER OF HEALTH IN ACCORDANCE WITH THE PROVISIONS OF  SUBDIVISION
TWELVE OF THIS SECTION.
  S  2. Subparagraph (viii) of paragraph (e) of subdivision 1 of section
7101-a of the education law, as added by chapter  517  of  the  laws  of
1995,  is  amended  and  a  new  subparagraph  (ix)  is added to read as
follows:
  (viii) artificial tears and lubricants[.];
  (IX) SUCH ADDITIONAL CATEGORIES OF DRUGS AS MAY BE RECOMMENDED BY  THE
COMMISSIONER  OF HEALTH IN ACCORDANCE WITH THE PROVISIONS OF SUBDIVISION
TWELVE OF THIS SECTION.
  S 3. Subdivision 1 of section 7101-a of the education law  is  amended
by adding a new paragraph (g) to read as follows:
  (G)  PHASE THREE THERAPEUTIC PHARMACEUTICAL AGENTS. PHASE THREE THERA-
PEUTIC PHARMACEUTICAL AGENTS SHALL MEAN THOSE ORALLY ADMINISTERED  DRUGS

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD03208-02-3

A. 2192                             2

USED  FOR  THERAPEUTIC PURPOSES FOR THE TREATMENT OF DISEASES OF THE EYE
AND ADNEXA AND SHALL BE LIMITED TO:
  (I) ANTIBIOTICS;
  (II) DECONGESTANTS/ANTI-ALLERGENIC/ANTIHISTAMINES;
  (III) ANTIGLAUCOMAS;
  (IV) ANTIVIRALS;
  (V)  ANALGESICS,  EXCEPT  THOSE  LISTED  IN  SCHEDULES I AND II OF THE
UNIFORM CONTROLLED SUBSTANCES ACT;
  (VI) NONSTEROIDAL ANTI-INFLAMMATORY DRUGS;
  (VII) SUCH ADDITIONAL CATEGORIES OF DRUGS AS MAY BE RECOMMENDED BY THE
COMMISSIONER OF HEALTH IN ACCORDANCE WITH THE PROVISIONS OF  SUBDIVISION
TWELVE OF THIS SECTION.
  S  4. Paragraphs (c) and (d) of subdivision 4 of section 7101-a of the
education law are relettered paragraphs (d) and (e) and a new  paragraph
(c) is added to read as follows:
  (C) BEFORE USING OR PRESCRIBING PHASE THREE THERAPEUTIC PHARMACEUTICAL
AGENTS, AN OPTOMETRIST MUST BE CERTIFIED TO PRESCRIBE DIAGNOSTIC PHARMA-
CEUTICAL  AGENTS  AND PHASE ONE AND PHASE TWO THERAPEUTIC PHARMACEUTICAL
AGENTS AND HAVE COMPLETED A TWENTY-FIVE  HOUR  PHASE  THREE  THERAPEUTIC
PHARMACEUTICAL   AGENT   CERTIFICATION  COURSE  OF  DIDACTIC  EDUCATION,
PROVIDED BY AN ACCREDITED COLLEGE  OF  OPTOMETRY  AND  APPROVED  BY  THE
DEPARTMENT,  WHICH  SHALL INCLUDE, BUT NOT BE LIMITED TO, INSTRUCTION IN
PHARMACOLOGY AND DRUG INTERACTION.
  SUCH COURSE SHALL QUALIFY TOWARDS  MEETING  THE  THIRTY-SIX  HOURS  OF
CONTINUING  EDUCATION  PER  TRIENNIAL  REGISTRATION  PERIOD  REQUIRED BY
SUBDIVISION SEVEN OF THIS SECTION. THIS REQUIREMENT FOR THE  TWENTY-FIVE
HOUR  PHASE  THREE THERAPEUTIC PHARMACEUTICAL AGENT CERTIFICATION COURSE
SHALL NOT APPLY TO THOSE OPTOMETRISTS WHO (I) GRADUATED FROM AN  ACCRED-
ITED COLLEGE OF OPTOMETRY SUBSEQUENT TO JANUARY FIRST, TWO THOUSAND FOUR
AND  (II)  HAVE  TAKEN  AND SUCCESSFULLY PASSED EITHER THE TREATMENT AND
MANAGEMENT OF OCULAR DISEASES PORTION OF THE NATIONAL BOARD OF EXAMINERS
IN OPTOMETRY OR AN EXAMINATION ACCEPTABLE TO THE BOARD.
  S 5. Subdivision 5 of section 7101-a of the education law, as added by
chapter 517 of the laws of 1995, is amended to read as follows:
  5. Suspension of  certification.  The  department  shall  suspend  the
certification  for  the  use  and  prescribing  of phase one therapeutic
agents of any optometrist who fails to receive certification  for  phase
two  therapeutic pharmaceutical agents within three years of having been
certified for phase one therapeutic pharmaceutical agents.  THE  DEPART-
MENT  SHALL  SUSPEND  THE  CERTIFICATION  FOR THE USE AND PRESCRIBING OF
PHASE ONE AND PHASE TWO THERAPEUTIC AGENTS OF ANY OPTOMETRIST WHO  FAILS
TO  RECEIVE  CERTIFICATION  FOR  PHASE  THREE THERAPEUTIC PHARMACEUTICAL
AGENTS WITHIN THREE YEARS OF APPROVAL BY THE DEPARTMENT OF A TWENTY-FIVE
HOUR PHASE THREE THERAPEUTIC PHARMACEUTICAL AGENT  CERTIFICATION  COURSE
PURSUANT TO PARAGRAPH (C) OF SUBDIVISION FOUR OF THIS SECTION.
  S 6. Subdivision 7 of section 7101-a of the education law, as added by
chapter 517 of the laws of 1995, is amended to read as follows:
  7.  Continuing  education. Each optometrist certified to use phase one
[or], phase two, OR PHASE THREE therapeutic pharmaceutical agents  shall
complete  a  minimum  of  thirty-six  hours  of continuing education per
triennial registration period. The education shall be  in  the  area  of
ocular  disease  and  pharmacology,  AT  LEAST  SIX HOURS OF WHICH SHALL
RELATE SPECIFICALLY TO  SYSTEMIC  DRUG  USE  AND  INTERACTION,  and  may
include both didactic and clinical components. Such educational programs
shall  be  approved  in  advance  by  the department and evidence of the
completion of this requirement shall be submitted with each  application

A. 2192                             3

for  license  renewal  as  required by section sixty-five hundred two of
this chapter.
  S  7.  Subdivision 12 of section 7101-a of the education law, as added
by chapter 517 of the laws of 1995, is amended to read as follows:
  12. Responsibilities of the commissioner of health.  The  commissioner
of  health  [may recommend to the commissioner additions or deletions to
the department's regulations relating to optometric use of drugs  except
that  such recommendations shall be limited only to additions which have
been determined to be equivalent to those drugs  already  authorized  or
deletions  based upon a finding that the drugs are no longer appropriate
for their current use or for other similar reasons.] SHALL RECOMMEND  TO
THE  COMMISSIONER ADDITIONS OR DELETIONS TO THE LIST OF APPROVED CATEGO-
RIES OF DIAGNOSTIC, THERAPEUTIC AND ORAL PHARMACEUTICAL AGENTS WHICH ARE
CONSISTENT WITH THE STANDARD OF CARE IN THE COMMUNITY FOR THE  DIAGNOSIS
AND TREATMENT OF DISEASES OF THE EYE AND ADNEXA.
  S  8.  Section  7106  of  the education law is amended by adding a new
subdivision 4 to read as follows:
  4. BEGINNING JANUARY FIRST, TWO THOUSAND FIFTEEN, AN APPLICANT  FOR  A
LICENSE  PURSUANT TO SECTION SEVENTY-ONE HUNDRED FOUR OF THIS ARTICLE OR
RENEWAL OF A REGISTRATION IN OPTOMETRY SHALL AFFIRM  TO  THE  DEPARTMENT
THAT  SUCH APPLICANT IS CERTIFIED IN CARDIOPULMONARY RESUSCITATION (CPR)
FROM AN APPROVED PROVIDER. IN THE EVENT THE APPLICANT CANNOT  PHYSICALLY
PERFORM CPR, THE COMMISSIONER'S REGULATIONS SHALL ALLOW THE APPLICANT TO
MAKE  ARRANGEMENTS  FOR  ANOTHER  INDIVIDUAL IN THE OFFICE TO ADMINISTER
CPR.
  S 9. This act shall take effect on the one hundred twentieth day after
it shall have become a law; provided that any rule or regulation  neces-
sary  for  the  timely  implementation of this act on its effective date
shall be promulgated on or before such effective date.

co-Sponsors

View additional co-sponsors

multi-Sponsors

View additional multi-sponsors

2013-A2192A (ACTIVE) - Details

See Senate Version of this Bill:: S7678
Current Committee:: Assembly Higher Education
Law Section:: Education Law
Laws Affected:: Amd §7101-a, Ed L
Versions Introduced in Other Legislative Sessions:: 2009-2010: A3718
2011-2012: A363

2013-A2192A (ACTIVE) - Summary

2013-A2192A (ACTIVE) - Bill Text download pdf

                            
                    S T A T E   O F   N E W   Y O R K
________________________________________________________________________

                                 2192--A

                       2013-2014 Regular Sessions

                          I N  A S S E M B L Y

                               (PREFILED)

                             January 9, 2013
                               ___________

Introduced  by  M.  of  A.  PAULIN, COOK, CYMBROWITZ, ABINANTI, GUNTHER,
  FARRELL, WEPRIN, HEVESI, RYAN, TITUS,  STIRPE,  SKOUFIS,  BUCHWALD  --
  Multi-Sponsored  by  --  M.  of  A.  CAHILL, CROUCH, DiPIETRO, FRIEND,
  GALEF, GOODELL, GOTTFRIED, HIKIND, KEARNS, RIVERA, SIMANOWITZ, SKARTA-
  DOS, STEC -- read once and referred to the Committee on Higher  Educa-
  tion -- recommitted to the Committee on Higher Education in accordance
  with  Assembly  Rule  3, sec. 2 -- committee discharged, bill amended,
  ordered reprinted as amended and recommitted to said committee

AN ACT to amend the education law, in relation to the practice of  opto-
  metry

  THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
BLY, DO ENACT AS FOLLOWS:

  Section 1. Subdivision 1 of section 7101-a of  the  education  law  is
amended by adding a new paragraph (g) to read as follows:
  (G)  PHASE THREE THERAPEUTIC PHARMACEUTICAL AGENTS. PHASE THREE THERA-
PEUTIC PHARMACEUTICAL AGENTS SHALL MEAN THOSE ORALLY ADMINISTERED  DRUGS
USED  FOR  THERAPEUTIC PURPOSES FOR THE TREATMENT OF DISEASES OF THE EYE
AND ADNEXA AND SHALL BE LIMITED TO:
  (I) ANTIBIOTICS;
  (II) DECONGESTANTS/ANTI-ALLERGENIC/ANTIHISTAMINES;
  (III) ANTIGLAUCOMAS; PROVIDED HOWEVER, WHEN PRESCRIBED OR ADMINISTERED
FOR THE TREATMENT OF ACUTE ANGLE CLOSURE GLAUCOMA, THE PRESCRIBING OPTO-
METRIST SHALL MAKE ALL  REASONABLE  EFFORTS  IMMEDIATELY  THEREAFTER  TO
REFER  THE  PATIENT  TO A LICENSED PHYSICIAN SPECIALIZING IN DISEASES OF
THE EYE AND PROVIDE NOTIFICATION IN ACCORDANCE WITH SUBDIVISION SIX-A OF
THIS SECTION;
  (IV) ANTIVIRALS;
  (V) ONE THREE-DAY SUPPLY OF ANALGESICS, BUT SHALL  NOT  INCLUDE  THOSE
LISTED IN SCHEDULES I AND II OF THE UNIFORM CONTROLLED SUBSTANCES ACT;
  (VI) NONSTEROIDAL ANTI-INFLAMMATORY DRUGS;

 EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                      [ ] is old law to be omitted.

                                                           LBD03208-06-4

A. 2192--A                          2

  (VII) ONE FOURTEEN-DAY SUPPLY OF CORTICOSTEROIDS.
  S  2. Paragraphs (c) and (d) of subdivision 4 of section 7101-a of the
education law are relettered paragraphs (d) and (e) and a new  paragraph
(c) is added to read as follows:
  (C) BEFORE USING OR PRESCRIBING PHASE THREE THERAPEUTIC PHARMACEUTICAL
AGENTS, AN OPTOMETRIST MUST BE CERTIFIED TO PRESCRIBE DIAGNOSTIC PHARMA-
CEUTICAL  AGENTS  AND PHASE ONE AND PHASE TWO THERAPEUTIC PHARMACEUTICAL
AGENTS AND HAVE COMPLETED A THIRTY HOUR PHASE THREE THERAPEUTIC  PHARMA-
CEUTICAL  AGENT  CERTIFICATION COURSE, WITH A CURRICULUM DEVELOPED BY AN
ACCREDITED COLLEGE OF OPTOMETRY IN COLLABORATION WITH A NEW  YORK  STATE
ACCREDITED  MEDICAL  SCHOOL.  THE CURRICULUM, WHICH SHALL BE APPROVED BY
THE DEPARTMENT, SHALL INCLUDE, BUT NOT BE  LIMITED  TO,  INSTRUCTION  IN
PHARMACOLOGY  AND  DRUG  INTERACTION AND BE TAUGHT THROUGH CLINICAL CASE
SCENARIOS AND EMPHASIZE CLINICAL DECISION MAKING.    SUCH  COURSE  SHALL
QUALIFY TOWARDS MEETING THE THIRTY-SIX HOURS OF CONTINUING EDUCATION PER
TRIENNIAL  REGISTRATION  PERIOD  REQUIRED  BY  SUBDIVISION SEVEN OF THIS
SECTION. THIS REQUIREMENT FOR THE THIRTY HOUR  PHASE  THREE  THERAPEUTIC
PHARMACEUTICAL AGENT CERTIFICATION COURSE SHALL NOT APPLY TO THOSE OPTO-
METRISTS  WHO  (I)  GRADUATED  FROM  AN  ACCREDITED COLLEGE OF OPTOMETRY
SUBSEQUENT TO JANUARY FIRST, TWO THOUSAND FOUR AND (II) HAVE  TAKEN  AND
SUCCESSFULLY  PASSED  EITHER  THE  TREATMENT  AND  MANAGEMENT  OF OCULAR
DISEASES PORTION OF THE NATIONAL BOARD OF EXAMINERS IN OPTOMETRY  OR  AN
EXAMINATION ACCEPTABLE TO THE BOARD.
  S 3. Subdivision 5 of section 7101-a of the education law, as added by
chapter 517 of the laws of 1995, is amended to read as follows:
  5.  Suspension  of  certification.  The  department  shall suspend the
certification for the use  and  prescribing  of  phase  one  therapeutic
agents  of  any optometrist who fails to receive certification for phase
two therapeutic pharmaceutical agents within three years of having  been
certified  for phase one therapeutic pharmaceutical agents.  THE DEPART-
MENT SHALL SUSPEND THE CERTIFICATION FOR  THE  USE  AND  PRESCRIBING  OF
PHASE  ONE AND PHASE TWO THERAPEUTIC AGENTS OF ANY OPTOMETRIST WHO FAILS
TO RECEIVE CERTIFICATION  FOR  PHASE  THREE  THERAPEUTIC  PHARMACEUTICAL
AGENTS WITHIN THREE YEARS OF APPROVAL BY THE DEPARTMENT OF A THIRTY HOUR
PHASE THREE THERAPEUTIC PHARMACEUTICAL AGENT CERTIFICATION COURSE PURSU-
ANT TO PARAGRAPH (C) OF SUBDIVISION FOUR OF THIS SECTION.
  S  4.  The opening paragraph of subdivision 6 of section 7101-a of the
education law, as added by chapter 517 of the laws of 1995,  is  amended
and two new subdivisions 6-a and 6-b are added to read as follows:
  Consultation  WITH USE OF CERTAIN PHASE TWO THERAPEUTIC PHARMACEUTICAL
AGENTS.
  6-A. NOTIFICATION OF USE OF  PHASE  THREE  THERAPEUTIC  PHARMACEUTICAL
AGENTS.  AN  OPTOMETRIST  SHALL, AS SOON AS PRACTICABLE, DOCUMENT IN THE
PATIENT'S RECORD THE PRESCRIPTION OR  USE  OF  PHASE  THREE  THERAPEUTIC
PHARMACEUTICAL  AGENTS. WITHIN SEVENTY-TWO HOURS OF PRESCRIBING OR USING
A PHASE THREE THERAPEUTIC PHARMACEUTICAL  AGENT,  AN  OPTOMETRIST  SHALL
NOTIFY  THE  PATIENT'S  PRIMARY  CARE  PRACTITIONER,  AND  DOCUMENT SUCH
NOTIFICATION WITH THE FOLLOWING INFORMATION:
  (I) THE NAME OF SUCH AGENT;
  (II) THE DOSE;
  (III) THE FREQUENCY OF USE; AND
  (IV) THE DURATION OF USE OR PRESCRIPTION.
  6-B. CONSULTATION WITH USE OF PHASE THREE  THERAPEUTIC  PHARMACEUTICAL
AGENTS.  IF IN THE PROFESSIONAL JUDGMENT OF THE OPTOMETRIST, A PATIENT'S
CONDITION DOES NOT RESULT IN AN ADEQUATE CLINICAL RESPONSE TO THE  PHASE
THREE  THERAPEUTIC  PHARMACEUTICAL  AGENT THERAPY, THE OPTOMETRIST SHALL

A. 2192--A                          3

CONSULT WITH THE PATIENT'S PRIMARY CARE PRACTITIONER AS  SOON  AS  CLIN-
ICALLY PRUDENT.
  S 5. Subdivision 7 of section 7101-a of the education law, as added by
chapter 517 of the laws of 1995, is amended to read as follows:
  7.  Continuing  education. Each optometrist certified to use phase one
[or], phase two, OR PHASE THREE therapeutic pharmaceutical agents  shall
complete  a  minimum  of  thirty-six  hours  of continuing education per
triennial registration period. The education shall be  in  the  area  of
ocular  disease  and  pharmacology,  AT  LEAST  SIX HOURS OF WHICH SHALL
RELATE SPECIFICALLY TO  SYSTEMIC  DRUG  USE  AND  INTERACTION,  and  may
include both didactic and clinical components. Such educational programs
shall  be  approved  in  advance  by  the department and evidence of the
completion of this requirement shall be submitted with each  application
for  license  renewal  as  required by section sixty-five hundred two of
this chapter.
  S 6. The opening paragraph of subdivision 8 of section 7101-a  of  the
education  law,  as added by chapter 517 of the laws of 1995, is amended
to read as follows:
  Notice to patient WITH USE OF CERTAIN PHASE TWO THERAPEUTIC PHARMACEU-
TICAL AGENTS.
  S 7. Subdivision 10 of section 7101-a of the education law,  as  added
by chapter 517 of the laws of 1995, is amended to read as follows:
  10.  Pharmaceutical  agents.  Optometrists  who have been approved and
certified by the department shall be  permitted  to  use  the  following
drugs:
  (a) Diagnostic pharmaceuticals.
  (b) Those optometrists having been certified for phase one therapeutic
pharmaceutical  agents shall be authorized [(i) to use and recommend all
nonprescription  medications  appropriate  for  ocular  disease  whether
intended  for  topical  or  oral use; and (ii)] to use and prescribe all
phase one therapeutic pharmaceutical agents which are FDA  approved  and
commercially available.
  In the event an optometrist treats a patient with topical antiviral or
steroidal  drugs  and the patient's condition either fails to improve or
worsens within five days,  the  optometrist  shall  notify  a  physician
designated by the patient or, if none, by the treating optometrist.
  (c) Those optometrists having been certified for phase two therapeutic
pharmaceutical agents shall be authorized to use and prescribe phase two
therapeutic pharmaceutical agents which are FDA approved and commercial-
ly available.
  (D) THOSE OPTOMETRISTS HAVING BEEN CERTIFIED FOR PHASE THREE THERAPEU-
TIC PHARMACEUTICAL AGENTS SHALL BE AUTHORIZED TO USE AND PRESCRIBE PHASE
THREE  THERAPEUTIC  PHARMACEUTICAL  AGENTS  WHICH  ARE  FDA APPROVED AND
COMMERCIALLY AVAILABLE.
  (E) THOSE OPTOMETRISTS HAVING BEEN CERTIFIED FOR PHASE ONE, PHASE  TWO
OR  PHASE THREE THERAPEUTIC PHARMACEUTICAL AGENTS SHALL BE AUTHORIZED TO
USE AND RECOMMEND ALL NONPRESCRIPTION MEDICATIONS, WHETHER INTENDED  FOR
TOPICAL  OR  ORAL  USE,  APPROPRIATE  FOR  THE  TREATMENT OF THE EYE AND
ADNEXA.
  S 8. Subdivision 12 of section 7101-a of the education law,  as  added
by chapter 517 of the laws of 1995, is amended to read as follows:
  12. Responsibilities of the commissioner of health.  [The] IN ORDER TO
SATISFY THE REQUIREMENT THAT AN OPTOMETRIST AUTHORIZED TO USE PHARMACEU-
TICAL AGENTS FOR USE IN THE DIAGNOSIS, TREATMENT OR PREVENTION OF OCULAR
DISEASE  SHALL BE HELD TO THE SAME STANDARD OF CARE IN DIAGNOSIS, USE OF
SUCH AGENTS, AND TREATMENT AS  THAT  DEGREE  OF  SKILL  AND  PROFICIENCY

A. 2192--A                          4

COMMONLY EXERCISED BY A PHYSICIAN IN THE SAME COMMUNITY, THE commission-
er  of  health [may recommend to the commissioner additions or deletions
to the department's regulations relating  to  optometric  use  of  drugs
except  that  such  recommendations  shall  be limited only to additions
which have been determined to  be  equivalent  to  those  drugs  already
authorized or deletions based upon a finding that the drugs are no long-
er  appropriate  for  their  current  use or for other similar reasons.]
SHALL RECOMMEND TO THE COMMISSIONER ADDITIONS OR DELETIONS TO  THE  LIST
OF  APPROVED  CATEGORIES  OF DIAGNOSTIC, THERAPEUTIC AND ORAL PHARMACEU-
TICAL AGENTS WHICH ARE CONSISTENT WITH  THE  STANDARD  OF  CARE  IN  THE
COMMUNITY  FOR  THE  DIAGNOSIS  AND TREATMENT OF DISEASES OF THE EYE AND
ADNEXA.
  S 9. This act shall take effect on the one hundred twentieth day after
it shall have become a law; provided that any rule or regulation  neces-
sary  for  the  timely  implementation of this act on its effective date
shall be promulgated on or before such effective date.

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Assembly Bill A2192A

Share this bill

Sponsored By

PAULIN

Archive: Last Bill Status - In Assembly Committee

Bill Amendments

co-Sponsors

Vivian Cook

Steven Cymbrowitz

Thomas Abinanti

Aileen Gunther

multi-Sponsors

Kevin Cahill

David DiPietro

Christopher Friend

Sandy Galef

2013-A2192 - Details

2013-A2192 - Summary

2013-A2192 - Bill Text download pdf

co-Sponsors

Vivian Cook

Steven Cymbrowitz

Thomas Abinanti

Aileen Gunther

multi-Sponsors

Kevin Cahill

Clifford Crouch

David DiPietro

Christopher Friend

2013-A2192A (ACTIVE) - Details

2013-A2192A (ACTIVE) - Summary

2013-A2192A (ACTIVE) - Bill Text download pdf

Comments